News
1 minute read

MBHB Partner Kevin Noonan Quoted in BioPharma Article Entitled, "Zarxio One Year On: U.S. Biosimilars Market Still Riddled With Uncertainty, Expert"

McDonnell Boehnen Hulbert & Berghoff LLP partner Dr. Kevin Noonan is quoted in a March 9, 2016 online edition of BioPharma in an article entitled, “Zarxio One Year On: U.S. Biosimilars Market Still Riddled With Uncertainty, Expert.” It is still too early to tell how big an impact biosimilars will have in the US, according to an IP lawyer, a year after the FDA approved Sandoz’s Zarxio. View the article